Indeed, VEGF-signalling inhibition with the small-molecule VEGFR inhibitor sunitinib in B16 murine melanoma models has been found to promote vascular normalisation, restore adhesion molecule expression and enhance CXCL10 and CXCL11 expression, which together increased CD8+ T-cell infiltration.78 Although these anti-angiogenic agents show limited therapeutic efficacy as monotherapies, their efficacy may be improved by using them in combination with immunotherapy. This evidence concerns the gene CXCL10 and melanoma.